340B pilot update: What U.S. providers should be tracking now
The 340B Model Pilot Program—launched by the Health Resources and Services Administration (HRSA) and designed to reshape how drug discounts are delivered—is expected to return with revisions informed by recent stakeholder feedback.
HRSA is still reviewing comments from the period that closed April 20, 2026. A draft notice in the coming weeks would signal the program remains on track for a Jan. 1, 2027, implementation.
What the 340B pilot is expected to do
At a high level, the model reflects broader efforts to modernize pricing oversight as Medicare drug pricing reforms take hold.
- Support claims-level data sharing between providers and manufacturers
- Help prevent duplicate discounts tied to Medicare price negotiations under the Inflation Reduction Act
- Improve visibility into how 340B discounts are applied
Operational considerations for healthcare providers, if ultimately a rebate model
As originally proposed, a rebate model introduces new processes that may require adjustments for many organizations.
- Post-purchase rebates: Hospitals would purchase drugs upfront and later receive rebates
- Additional data reporting: Would be required to support claims-level tracking
- New workflows: Could potentially add administrative steps across pharmacy and finance teams
Some providers may need to evaluate system readiness and internal coordination.
Evolving expectations from drug manufacturers
At the same time, certain drug manufacturers are seeking more detailed claims data, requiring both retail and medical information and prompting providers to align their internal systems and processes accordingly. They seek a more structured, intentional approach to data transparency, signaling heightened expectations.
Legal challenges to 340B pricing access
A U.S. federal court recently overturned the HRSA policy that required new child sites (offsite facilities) to be listed on a hospital’s cost report before assessing 340B pricing. This would allow hospitals to access pricing for new facilities sooner. Under the original policy, hospitals often had to wait months, sometimes nearly two years, for their new sites to qualify for 340B pricing.
HRSA is appealing the court’s ruling. If the appeal is successful, requirements for pricing eligibility could revert, and hospitals that access savings under the new ruling could face repayment risk.
Looking ahead
For healthcare providers, the 340B environment is becoming more data-driven, interconnected and operationally complex. Organizations that take a proactive approach will be better positioned to adapt as details continue to evolve.
- Strengthen data infrastructure: Ensure claims data can be captured, validated and shared efficiently across systems.
- Align internal stakeholders: Pharmacy, finance, compliance and IT teams will need tighter coordination.
- Evaluate cash flow impacts: Rebate timing may shift how organizations manage working capital.
- Monitor policy and legal updates: Timing and final requirements remain fluid.
Learn more about what’s happening in health care in our industry outlook.
